Anagenesis Biotechnologies

Anagenesis Biotechnologies is a preclinical‐stage biotech company focused on developing novel treatments for muscle degenerative and metabolic diseases with unmet medical needs. Anagenesis Biotechnologies secured private investments from the AFM-Telethon (French muscular dystrophy association), Cap Innov'Est and Boehringer Ingelheim Venture Fund.